



EGYPTIAN ACADEMIC JOURNAL OF
BIOLOGICAL SCIENCES

MEDICAL ENTOMOLOGY & PARASITOLOGY


E



ISSN
2090-0783

WWW.EAJBS.EG.NET

Vol. 15 No. 2 (2023)



Concomitant Infection of *Helicobacter pylori* and Intestinal Parasites in Children Attending Benha University Hospital

Gehad A. Basuony¹, Hager A. Basuony² and Efat Asser²

¹Parasitology Department, Kasr Al Ainy School of Medicine, Cairo University.

²Pediatric Department, Faculty of Medicine, Benha University.

*E-mail : gehadahmed@kasralainy.edu.eg

ARTICLE INFO

Article History

Received:22/10/2023

Accepted:15/12/2023

Available:19/12/2023

Keywords:

Concomitant infection;
Helicobacter pylori; intestinal parasites. ; virulence ;Caga factor .

ABSTRACT

Background: Children frequently experience gastrointestinal (GI) symptoms such as diarrhoea and stomach pain. Intestinal parasites and *Helicobacter pylori* are prevalent causes of GI pain and important infectious pathogens burdening global public health. The present study's objective is to determine how *H. pylori* infections and related intestinal parasites affect paediatric patients' clinical presentation. **Methods:** This cross-sectional study included 70 children less than 18 years old of both sexes suffering from GI symptoms suggestive of intestinal parasitic or *H. pylori* infection and admitted to Benha University Hospitals' paediatric department. Every patient underwent a thorough history review, physical examination, and laboratory analysis. The source of the water supply, a history of GI manifestations such like diarrhoea, abdominal pain, abdominal swelling, vomiting, hematemesis, or rectal bleeding, as well as the results of the endoscopy. Patients were also tested for the presence of intestinal parasites and *H. pylori* infection by testing for *H. pylori* stool antigens, additionally, all stool samples were tested for the existence of helminthic and/or protozoal diseases. *H. pylori* caga virulence factor was analysed by real-time PCR**Results:** Twenty-six (37.1%) patients were positive for *H. pylori* infection, 23 (32.9%) had a parasitic infection and 21 (30.0%) had a concomitant infection (*H. pylori* and parasites). Clinical manifestations (abdominal pain, abdominal distension, vomiting and diarrhea) were insignificantly different among the studied groups. **Conclusions:** Additional research is necessary to understand the mutual impact of co-infection between *H. pylori* and other parasites on immunological, molecular and ultrastructural levels, and the consequent effect on the emergence of various clinical presentations.

INTRODUCTION

Children frequently experience gastrointestinal (GI) problems like diarrhoea and abdominal discomfort. Every year, there are over 1.7 billion cases of paediatric diarrhoea worldwide (Selbuz and Buluş, 2020). *Giardia lamblia*, *Entamoeba histolytica*, and *Cryptosporidium* species. are only a few of the pathogenic organisms that can cause diarrhoea in children (Verma *et al.*, 2019).

Intestinal parasites and *Helicobacter pylori* are infectious diseases with significant global public health implications and are typical causes of GI disorders (Pomari *et al.*, 2020). Attributable to inadequate sanitation, contaminated water, hot, humid weather, inadequate housing, and overcrowding, intestinal parasites are a key contributor to sickness and mortality, particularly in developing nations (Al-Yousofi *et al.*, 2022).

A Gram-negative bacterium known as *H. pylori* is linked to both stomach cancer and peptic ulcers. The prevalence of *H. pylori* infection is estimated to be greater than 50% worldwide with low- and middle-income countries having the largest burden (LMICs) (Savoldi *et al.*, 2018).

Similarly, intestinal parasites afflict millions of people worldwide, increasing the likelihood that they will also contract *H. pylori* (Majid *et al.*, 2019).

Numerous investigations have identified *H. pylori* infection and intestinal parasitic infections, particularly giardiasis, as potential etiological causes for GI symptoms such as recurring stomach pain and diarrhoea. In underdeveloped nations, there is a significant amount of evidence linking *G. lamblia* infection with *H. pylori* infection. It is essential to choose an appropriate treatment to achieve infection eradication that takes into account the relationships between various infectious agents (Abd El Hameed *et al.*, 2021, Tilahun *et al.*, 2022).

The purpose of the current study is to assess the influence of *H. pylori* infection and concomitant intestinal parasitic infection on the clinical presentation of paediatric patients.

MATERIALS AND METHODS

This cross-sectional research included 70 children who were tested for the presence of intestinal parasites and *H. pylori* and were admitted to the Department of Pediatrics, Benha University Hospitals. The study was done after approval of the institutional ethical committee (Rc.13.8.2023). Consent to participate was obtained from the patients' guardians and proper management was performed according to diagnosis. The study was conducted between the months of March 2022 to March 2023.

Inclusion criteria: Patient's age <18 years old, both sexes, complaining of GI symptoms suggestive of intestinal parasites and/or *H. pylori* infection.

Exclusion criteria: Patient's refusal to participate, children of patients who underwent antiparasitic, antibiotic, or *H. pylori* medication within the previous month before visiting the GI clinics. Additionally, other causes of GI symptoms such as bacterial or viral infections, or other dietary or nutritional problems were ruled out from the study.

Every patient underwent a thorough history-taking procedure (age, sex, BMI and residency). Patients were asked about water sources and previous GI problems such as diarrhoea hematemesis or rectal haemorrhage, abdominal distension, nausea, and stomach pain. Results of endoscopic procedures, such as investigating the presence of chronic gastritis and antral gastritis, bulbar duodenitis, and erosive duodenitis were also recorded.

Sample Collection and Processing:

Biopsy specimens' culture was performed in a biological safety cabin and then preserved at -80°C deep freezer for further molecular processing. The specimens were discharged with the aid of a sterile swab into two commercial culture media: blood agar (Columbia agar + 5% sheep blood, BioMérieux) and *Helicobacter* selective agar media (Pylori agar, BioMérieux). The samples were incubated for 15 days at 37°C in a micro-aerobic atmosphere (5% O_2 , 10% CO_2 , and 85% N_2). *H. pylori* colonies are small, translucent to yellowish colonies, which can be identified based on a Gram-negative helical-shaped in Gram-staining procedure followed by positive oxidase, catalase, and urease tests, along with the confirmation by MALDI-TOF mass spectrometry (Bruker).

In addition to testing for *H. pylori* stool antigens, all stool samples were tested for the existence of helminthic and/or protozoal diseases. The following procedures were used; each participant provided three consecutive faecal samples, which were all collected in a wide-mouthed, clean, dry container with a label (Ruenchit,

2021). The faeces cups were immediately brought to the lab for inspection, where the following was performed:

Direct wet mount smear method was studied under the microscope at low and high magnifications. The material was next examined for protozoa by applying an iodine drop onto the edge of the coverslip. The sample was concentrated utilizing formalin-ethyl acetate (FEA) sedimentation, which was followed by the transfer of the sediment to a clean glass slide for examination. Kinyoun's Acid-Fast stain was employed to permanently stain the smear, which was kept in 10% formalin (cold method). Every stool sample was exposed to copro-antigen detection utilizing an on-site *H. pylori* Ag fast test from CTK BIOTECH for the purpose of *H. pylori* antigen identification utilizing immunochromatographic immunoassay testing (ICT) (Bradbury *et al.*, 2022).

***H. pylori* Caga Virulence Factor Analysis by Real-Time PCR:**

Utilizing the MagNA Pure LC 2.0 Instrument, the entire DNA was taken from 200 mg of faeces (Roche, Monza, Italy). As an internal control for isolation and amplification procedures, *Phocine Herpes Virus type-1* (PhHV-1), was introduced to each sample (Perandin *et al.*, 2018). All the amplification reactions were conducted utilizing 5 µL of DNA and utilizing SsoAdvanced universal probes supermix (BioRad, Milan, Italy), primers cagA-F 5'-TCAAGAACCAGTTCCCATGTC-3' and cagA-R 5'-CTCTAGCTTCAGGCGGTAAGC-3', and probe HEX-5'-ACCAGATATAGCCACTACC-3'.

The programme was made up of 50 cycles of 15 seconds at 95 °C, 30 seconds at 58 °C, and 30 sec at 72 °C. The first phase took 3 minutes at 95 °C. The CFX96 system was utilized for all reactions and data analytics (BioRad, Milan, Italy) (Deng *et al.*, 2020).

Sample Size Calculation:

G. power 3.1.9.2 (Universität Kiel, Germany) was utilized to calculate the sample size. According to a prior study,

sample size was established by comparing the prevalence of GI symptoms (abdominal distension) in cases with *G. lamblia* infection to cases with *H. pylori* infection alone and instances with co-infection of both (58.8% vs. 45.8% vs. 71.4%) (Abd El Hameed *et al.*, 2021). According to the following criteria: 0.05 error and an 80 percent study power. To combat dropout, four additional cases were introduced. Seventy patients were assigned as a result.

Statistical Analysis:

SPSS version 28 was utilized for statistical analysis (IBM Inc., Armonk, NY, USA). The ANOVA (F) test was utilized to contrast the two sets of quantitative variables, which were provided as mean and standard deviation (SD). Chi-square test was utilized to analyze qualitative variables, which were provided as frequency and percentage. Diagnostic sensitivity was used to measure the incidence of true positive results in patients' groups. Statistical significance was deemed as a two tailed P value < 0.05.

RESULTS

In our study, 26 (37.1%) of patients had *H. pylori* infection, 23 (32.9%) had a parasitic infection and 21 (30.0%) had a concomitant infection (*H. pylori* and parasites). Table 1 shows the type of parasitic infection where *Blastocystis spp.* was the most widespread spp., the second most common being *E. coli* species.

Table 1: Distribution of parasitic infection.

Parasite	Parasitic infection (n=23)
Blastocystis spp.	11 (15.7%)
E. coli	6 (8.6%)
E. nana	4 (5.7%)
S. mansoni	4 (5.7%)
E. dispar	3 (4.3%)
D. fragilis	2 (2.9%)
E. histolytica	2 (2.9%)
G. intestinalis	2 (2.9%)
S. stercoralis	2 (2.9%)
E. hartmanni	1 (1.4%)
A. duodenale	1 (1.4%)
H. nana	1 (1.4%)

Data displayed as frequency (%)

Baseline characteristics (age, gender, weight, and height) and type of water supply were insignificantly different among the studied groups. Patients from

rural areas showed a significantly higher incidence of *H. pylori* infection ($P=0.020$) (Table 2).

Table 2: Baseline characteristics of the studied groups.

		H. pylori infection (n=26)	Parasitic infection (n=23)	Concomitant infection (n=21)	P value
Age (years)		9.31 ± 3.64	8.26 ± 4.21	10.29 ± 3.95	0.239
Gender	Male	12 (46.2%)	15 (65.2%)	10 (47.6%)	0.348
	Female	14 (53.8%)	8 (34.8%)	11 (52.4%)	
Weight (Kg)		26.35 ± 8.11	27.13 ± 8.13	26.57 ± 6.51	0.936
Height (cm)		120.12 ± 6.39	117.3 ± 10	119.95 ± 7.1	0.403
Residence	Urban	4 (15.4%)	12 (52.2%)	9 (42.9%)	0.020*
	Rural	22 (84.6%)	11 (47.8%)	12 (57.1%)	
Type of water supply					
Tap water		9 (34.6%)	10 (43.5%)	11 (52.4%)	0.807
Filtered water		7 (26.9%)	6 (26.1%)	4 (19%)	
Pumped water		10 (38.5%)	7 (30.4%)	6 (28.6%)	

Data displayed as mean ± SD or frequency (%), *: statistically significant as P value <0.05

Regarding the clinical manifestations, abdominal pain was recorded in 11 cases (42.3%) in the *H. pylori* group, 7 (30.4%) cases of the parasitic infection group and 6 cases (28.6%) in the concomitant infection group. Abdominal distension was reported in 8 cases (30.8%) in *H. pylori* group, 6 (26.1%) cases in the parasitic infection group and 7 (33.3%) cases in the concomitant infection group. Vomiting occurred in 5 (19.2%)

cases in *H. pylori* group, 2 (8.7%) cases in parasitic infection group and 2 (9.5%) cases in the concomitant infection group. Diarrhea occurred in 2 (7.7%) cases in the *H. pylori* group, 8 (34.8%) cases in the parasitic infection group and 6 (28.6%) cases in the concomitant infection group. There was no significant difference between the occurrence of clinical manifestations among the studied groups. (Fig. 1).




Fig. 1: Bar chart showing Clinical manifestations of the studied groups.

Regarding the endoscopic findings, chronic gastritis was recorded in 2 (7.69%) cases in *H. pylori* group, 4 (17.39%) cases parasitic infection group and 4 (19.05%) cases in the concomitant infection group. Chronic gastritis and erosive duodenitis occurred in 6 (23.08%) cases in *H. pylori* group, 6 (26.09%) cases

in parasitic infection group and 7 (33.33%) cases in the concomitant infection group. Antral gastritis and bulbar duodenitis occurred in 4 (15.38%) cases in *H. pylori* group, 2 (8.7%) cases in parasitic infection group and 3 (14.29%) cases in the concomitant infection group (Table 3).

Table 3 : Endoscopic findings of the studied groups.

	<i>H. pylori</i> infection (n=26)	Parasitic infection (n=23)	Concomitant infection (n=21)	P value
Chronic gastritis	2 (7.69%)	4 (17.39%)	4 (19.05%)	0.839
Chronic gastritis and erosive duodenitis	6 (23.08%)	6 (26.09%)	7 (33.33%)	
Antral gastritis and bulbar duodenitis	4 (15.38%)	2 (8.7%)	3 (14.29%)	

Data presented as frequency (%).

Regarding the genes distribution in *H. pylori* strains, 19 (73.07%) patients were positive for CagA and 7 (26.92%) patients were negative for CagA (Table 4).

Table 5, shows that there was significant correlation between *H. pylori* genotypes and abdominal pain and abdominal distension (P=0.033, 0.045), whereas there was insignificant correlation between *H. pylori* genotypes and other clinical manifestation (vomiting and diarrhea).

Table 4: Genes distribution in *H. pylori* strains of studied patients.

		n=26
CagA	Positive	19 (73.07%)
	Negative	7 (26.92%)

Data presented as frequency (%).

Table 5: Correlation between various *H. pylori* genotype and clinical manifestations.

	CagA Positive (n=19)	CagA Negative (n=7)	
Abdominal pain	8 (42.11%)	3 (42.86%)	0.033*
Abdominal distension	6 (31.58%)	2 (28.57%)	0.045*
Vomiting	4 (21.05%)	1 (14.29%)	0.057
Diarrhea	1 (5.26%)	1 (14.29%)	NS

*: statistically significant as P value <0.05.

Table 6: Comparison between molecular results and ICT results for *h. pylori* as regards sensitivity

	PCR	ICT
Positive	25	23
Negative	1	3
Sensitivity	96.15%	88.46%

PCR: polymerase chain reaction, ICT: immunochromatographic


Microscopic Findings:

Fig. 2: Light microscopic picture showing *Entamoeba histolytica* cyst stained with iodine (x 400).




Fig. 3: Light microscopic picture showing *Giardia* cyst and trophozoite stained with iodine (x 400).




Fig. 4: Light microscopic picture showing *Blastocystis* stained with iodine (x400).

DISCUSSION

A gram-negative bacillus called *Helicobacter pylori*, which colonises the gastrointestinal mucosa is commonly acquired throughout childhood and may linger into adulthood (Malfertheiner *et al.*, 2023). It could be asymptomatic or show a variety of GI symptoms, such as dyspepsia,

chronic epigastric discomfort, hematemesis, vomiting, ulcers, or even gastric cancer. There is considerable debate over the connection between *H. pylori* infection and diarrhoea in children (Kakiuchi *et al.*, 2019). *Monoclonal antibodies may identify H. pylori copro-antigen in stool with great specificity and*

sensitivity by utilising immunochromatography (Ng *et al.*, 2019, Obaid *et al.*, 2021).

In a cohort of adults visiting a centre for tropical disorders in North-Eastern Italy the vast majority of participants were from Africa (Pomari *et al.*, 2020). *H. pylori* infection was prevalent in most people, and most of them were *cagA*⁺, suggesting potential mechanisms of aiding the entry of other pathogens (Kusters *et al.*, 2006).

In our study, *H. pylori* infection affected 26 patients (37.1%) of the overall group, while parasitic infections affected 23 (32.9%) and concurrent infection affected 21 (30.0%) patients (*H. pylori* and parasites). Numerous investigations have demonstrated that intestinal parasites and *H. pylori* infection are related (El-Badry *et al.*, 2017, Ibrahim *et al.*, 2019, Spotts *et al.*, 2020).

Gastric juice normally produces an environment that is unfavourable to harmful germs. As stated by the location and length of the infection, *H. pylori* alters the gastric acid output. In addition, the bacteria can damage the gastric mucosal barrier, providing an ideal environment for intestinal parasitosis (Wroblewski *et al.*, 2010, Waldum *et al.*, 2016).

Ghallab and Morsy reported that *Cryptosporidium spp.* (32%), *Blastocystis* (68%), *E. histolytica* complex (27%), and *G. lamblia* (31%) were more prevalent in *H. pylori*-infected patients at Kafrelsheikh University Hospital than in individuals without the infection (Ghallab and Morsy, 2020).

It is important to note that polymicrobial interactions in the intricate intestinal niche can have a significant impact on how a disease develops (Frisan, 2021). In fact, the coexistence of intestinal protozoa and *H. pylori* might cause an increased T helper (Th1) response that worsens mucosal damage and does not successfully eliminate the infection (Hussain *et al.*, 2020). Few studies examined diabetic individuals'

simultaneous infection with *Cryptosporidium* and *H. pylori* (Htun *et al.*, 2018). In a study by Fadl *et al.*, 4 (10%) diabetic patients were found to have co-infections with *Cryptosporidium* and *H. pylori*, although there was no statistically significant variation between them and the three patients who also had *Blastocystis* infection (Fadl *et al.*, 2021). Pomari *et al.* studied concurrent infection of *H. pylori* and intestinal parasites in 93 subjects and found that 61 (66%) subjects had *H. pylori* infection (Pomari *et al.*, 2020).

In a study by Abd El Hameed *et al.*, 150 children of both sexes, ages 1 to 15 and suffering from gastrointestinal complaints were studied to ascertain the connection between *H. pylori* infection and parasitic diseases. They discovered that 88 patients (58.6%) had intestinal parasitic infection, and 63 patients (42%) tested positive for the *H. pylori* faecal antigen. Intestinal protozoa were substantially more common (92%) than intestinal helminths (Abd El Hameed *et al.*, 2021).

We discovered that *E. coli spp.* was the second most prevalent spp. after *Blastocystis spp.* Pomari *et al.* in their cohort, observed that those with intestinal parasitic infections had a greater incidence of *H. pylori* infection than did patients who were not affected. The interaction of *H. pylori* with *Blastocystis spp.* was the most abundantly reported, making it the most common type of intestinal parasite. A larger percentage of people with *E. coli* and *E. nana* infections were discovered among those who had *H. pylori* infection, despite that the association was not statistically significant (Pomari *et al.*, 2020).

A study done on 115 Egyptian patients with irritable bowel syndrome (IBS) revealed that 27% of those with *H. pylori* also had *Blastocystis* (El-Badry *et al.*, 2018). Recently, it was discovered that chronic diarrhoea in Pakistani patients was significantly correlated with *Blastocystis* and *H. pylori* coinfection (67 %) (Yakoob *et al.*, 2018).

In a prior study investigating the prevalence and subtypes of *Blastocystis*, it was shown that co-infection occurred in 46% of samples that tested positive for the parasite, with *D. fragilis* being the most common co-infecting parasite (Piubelli *et al.*, 2019). The most prevalent infections impacting people in low and middle-income countries were found to be *H. pylori*, *E. histolytica/dispar*, and *G. intestinalis* (Moreira *et al.*, 2005).

Moreover, Abd El Hameed *et al.* revealed that 75 patients had mono parasitic infections, with *G. lamblia* (35.2%) and the *Entamoeba histolytica/E. dispar* complex (22.7%) being the most frequently found parasites. *Blastocystis hominis* and *Hymenolepis nana* parasites were next in frequency. Thirteen patients had the mixed parasitic infection, with the following combinations: *Blastocystis hominis* and *Entamoeba histolytica/E. dispar* complex (5 patients), *Blastocystis hominis* and *G. lamblia* (3 patients), *G. lamblia* and *Entamoeba histolytica/E. dispar* complex (4 patients), *Entamoeba histolytica/E. dispar* complex and *Cryptosporidium*, and *Entamoeba histolytica/E. dispar* complex and *Crypto* (one patient), all without statistical significance (Abd El Hameed *et al.*, 2021). These findings were similar to outcomes by Cheng *et al.* in China and Hestvik *et al.* in Uganda who determined that that overall detection of *H. pylori* infection was 46.6 and 44.3 percent, respectively (Cheng *et al.*, 2009, Hestvik *et al.*, 2010). Previous work had examined the co-infection of *H. pylori* and parasitic illnesses (Seid *et al.*, 2018, Yousif Abd Elbagi *et al.*, 2019). Intestinal parasites and the *H. pylori* bacterium both colonize the gastrointestinal tract (GIT) and are common in young children. Additionally, similar mechanisms of transmission (such as the feco-oral route), low socioeconomic levels, and unsanitary environments may all contribute to the coexistence of both illnesses (Sabah *et al.*, 2015).

A comparable study that investigated 363 adult patients from

Ethiopia found that those with *H. pylori* infection had considerably greater *G. lamblia* prevalence (22.3%) than those without it (Seid *et al.*, 2018). Likewise, *G. intestinalis* was the predominant (20.1 %) coexisting parasite in 427 non-symptomatic children from Uganda with a prevalence of *H. pylori* of 44.3% (Ankarklev *et al.*, 2012). Moreira *et al.* did not discover a significant connection between *H. pylori* seropositivity and *E. histolytica* infection (Moreira *et al.*, 2005). However, Torres *et al.* indicated that those who carried the parasite *E. histolytica* had a considerably lower prevalence of *H. pylori* infection than those who did not. In order to determine the existence of an association, if any, well-designed cohort type research is required (Torres *et al.*, 2003).

In a study by Pomari *et al.*, both *Blastocystis* and *H. pylori* were frequently identified in participants who tested positive. It is likely that their presence in the stool of those who had gastrointestinal symptoms was a coincidental discovery rather than a cause of their symptoms (Pomari *et al.*, 2020). An earlier study found that participants without IBS symptoms had a higher *D fragilis* proportion in fecal samples than participants Rome III criteria for IBS (35% vs 23%; $P = .03$), as was *Blastocystis* (22% of controls vs 15% of cases; $P = .09$), and a greater percentage of participants without IBS symptoms carried more than 1 species of parasite (16% of controls vs 8% of cases; $P = .05$) (Krogsgaard *et al.*, 2015).

In the current study, there were little differences in the clinical signs (abdominal discomfort, abdominal distension, vomiting, and diarrhoea) between the groups under study.

In various cases, the most often noted complaints were diarrhoea, distension, and abdominal pain. Okyay *et al.* and Escobedo *et al.* exhibited a significant correlation between parasite infections and diarrhoea or stomach pain (Okyay *et al.*, 2004, Escobedo *et al.*, 2008). Abd El Hameed *et al.* reported that cases with individual *H. pylori*

infection exhibited higher rates of vomiting and hematemesis (Abd El Hameed *et al.*, 2021). Dore *et al.* reported that children who had nausea or vomiting had a considerably greater rate of *H. pylori* infection compared to children who did not exhibit these symptoms. The distinction between the location of an infection for intestinal parasites (lower gastrointestinal tract) and *H. pylori* (upper gastrointestinal tract) may explain this variation in symptoms. However, diverse GIT symptoms found in patients (negative for both parasitic and *H. pylori* infection) were linked to other infectious (bacterial and viral) and non-infectious (dietary and feeding) reasons that had been identified (Dore *et al.*, 2012). In the group with an *H. pylori* infection, which occurred less frequently, diarrhoea was not considered to be a notable symptom (Abd El Hameed *et al.*, 2021). This may be attributed to the fact that the virulence factor of *H. pylori* (VAC A cytotoxin) in their study might not be the one which promotes diarrhea with *H. pylori* (Passaro *et al.*, 2001).

Unlike what we had anticipated, in a study by Abd El Hameed *et al.*, there was a statistically significant variation in the frequency of diarrhoea between cases with parasite and *H. pylori* co-infection (35.6%) and cases with parasitic infection alone (63.2%) (Abd El Hameed *et al.*, 2021). A number of studies have documented how *H. pylori* infection slows the progression of diarrhoea in *H. pylori*-infected individuals, which could be a result of the gastric immunological response being activated (Salama *et al.*, 2019).

Abdominal pain, distension and diarrhea were the most frequently recorded complaints among different cases and were found to be more frequent in cases of parasitic infection alone than those with *H. pylori* infection (Abd El Hameed *et al.*, 2021). Similarly, Okyay *et al.* and Escobedo *et al.* demonstrated strong association between parasitic infections and abdominal pain or diarrhea (Okyay *et al.*, 2004, Escobedo *et al.*, 2008). Vomiting is one of

the typical symptoms of *H. pylori* infection, coinfection cases were more likely to have hematemesis (17.9%) than those of *H. pylori* infection alone (37.5%) (Abd El Hameed *et al.*, 2021). Abd El Hameed *et al.* exhibited that *H. pylori* infection may be able to reduce the diarrhoea brought on by intestinal parasites. In contrast, parasitic infection may lessen the frequency of vomiting brought on by *H. pylori* infection in cases where both infections are present (Abd El Hameed *et al.*, 2021).

We found that of 26 positive cases, 19 (73.07%) patients were positive for CagA and 7 (26.92%) patients were negative for CagA.

In Khater *et al.* study, CagA positive were 50%, while 48.39% were negative for cagA and 1.61% was mixed (Hassan Khater and Alfaki, 2022). Similar results were obtained by Akeel *et al.*, who detected cagA in 49.2% of *H. pylori* strains (Akeel *et al.*, 2019). The results also were similar to the studies by Momenah *et al.*, Marie *et al.*, Kadi *et al.* 14 in Saudi Arabia, they found cagA prevalences were 52.4%, 62% and 81.8% respectively (Momenah and Tayeb, 2007, Marie, 2012, Kadi *et al.*, 2014). In Egypt, Abu Taleb *et al.* reported the prevalence of cagA was about 57% in their studied group (Abu-Taleb *et al.*, 2018).

Our study had several limitations because it was a single-center study with a small sample size.

Conclusions: Additional research on the impact of co-infection on the fine structures of *H. pylori* and other parasites may be necessary to understand the effects of the two organisms on one another, and ultimately on the emergence of various clinical presentations in patients.

Financial support and sponsorship: Nil

Conflict of Interest: Nil

Ethical Statements: Approval of the institutional ethical committee (Rc.13.8.2023) at Faculty of Medicine Benha university.

REFERENCES

- Abd El Hameed, Y. F., Boghdadi, A. M., Ghobrial, C. M. & Hassan, M. A. 2021. Association of *Helicobacter pylori* and parasitic infections in childhood: impact on clinical manifestations and implications. *Journal of Parasitic Diseases*, 45, 790-796.
- Abu-Taleb, A. M. F., Abdelattef, R. S., Abdel-Hady, A. A., Omran, F. H., El-Korashi, L. A., Abdel-Aziz El-Hady, H., et al. 2018. Prevalence of *Helicobacter pylori* *cagA* and *iceA* genes and their association with gastrointestinal diseases. *International Journal of Microbiology*, 2018, 480-9.
- Akeel, M., Shehata, A., Elhafey, A., Elmakki, E., Aboshouk, T., Ageely, H., et al. 2019. *Helicobacter pylori* *vacA*, *cagA* and *iceA* genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes. *BMC Gastroenterology*, 19, 16-23.
- Al-Yousofi, A., Yan, Y., Al Mekhlafi, A. M., Hezam, K., Abouelnazar, F. A., Al-Rateb, B., et al. 2022. Prevalence of Intestinal Parasites among Immunocompromised Patients, Children, and Adults in Sana'a, Yemen. *Journal of Tropical Medicine*, 2022, 59-63.
- Ankarklev, J., Hestvik, E., Lebbad, M., Lindh, J., Kaddu-Mulindwa, D. H., Andersson, J. O., et al. 2012. Common coinfections of *Giardia intestinalis* and *Helicobacter pylori* in non-symptomatic Ugandan children. *PLOS Neglected Tropical Diseases*, 6, 178-92.
- Bradbury, R. S., Sapp, S. G. H., Potters, I., Mathison, B. A., Frean, J., Mewara, A., et al. 2022. Where Have All the Diagnostic Morphological Parasitologists Gone? *Journal of Clinical Microbiology*, 60, 98-105.
- Cheng, H., Hu, F., Zhang, L., Yang, G., Ma, J., Hu, J., et al. 2009. Prevalence of *Helicobacter pylori* infection and identification of risk factors in rural and urban Beijing, China. *Helicobacter*, 14, 128-33.
- Deng, L., He, X. Y., Tang, B., Xiang, Y. & Yue, J. J. 2020. An improved quantitative real-time polymerase chain reaction technology for *Helicobacter pylori* detection in stomach tissue and its application value in clinical precision testing. *BMC Biotechnology*, 20, 33-8.
- Dore, M. P., Fanciulli, G., Tomasi, P. A., Raldi, G., Delitala, G., Graham, D. Y., et al. 2012. Gastrointestinal symptoms and *Helicobacter pylori* infection in school-age children residing in Porto Torres, Sardinia, Italy. *Helicobacter*, 17, 369-73.
- El-Badry, A. A., Abd El Wahab, W. M., Hamdy, D. A. & Aboud, A. 2018. Blastocystis subtypes isolated from irritable bowel syndrome patients and co-infection with *Helicobacter pylori*. *Parasitology Research*, 117, 127-137.
- El-Badry, A. A., Ghieth, M. A., Ahmed, D. A. & Ismail, M. A. M. 2017. *Giardia intestinalis* and *helicobacter pylori* co-infection: Estimated risks and predictive factors in egypt. *Journal of the Egyptian Society of Parasitology*, 47, 19-24.
- Escobedo, A. A., Cañete, R. & Núñez, F. A. 2008. Prevalence, risk factors and clinical features associated with intestinal parasitic infections in children from San Juan y Martínez, Pinar del Río, Cuba. *West Indian Medical Journal*, 57, 377-82.
- Fadl, H., Elsayed, N., Rehan, M., El-Gebaly, N. & Abdel-Shafi, I. 2021. Stressing a tired host: *Cryptosporidium* species and *Helicobacter pylori* infections in diabetes mellitus patients with gastrointestinal manifestations.

- Parasitologists United Journal*, 14, 261-268.
- Frisan, T. 2021. Co- and polymicrobial infections in the gut mucosa: The host-microbiota-pathogen perspective. *Cellular Microbiology*, 23, 132-9.
- Ghallab, M. M. I. & Morsy, S. M. 2020. Helicobacter pylori co-infected with common intestinal protozoa in gastrointestinal symptomatic patients. *Journal of the Egyptian Society of Parasitology*, 50, 390-393.
- Hassan Khater, E. S. & AlFaki, A. A. 2022. Detection of vacA, cagA and iceA genes of H. pylori in dyspeptic patients and their association with clinical data and histopathological abnormalities. *Egyptian Journal of Medical Microbiology*, 31, 99-107.
- Hestvik, E., Tylleskar, T., Kaddu-Mulindwa, D. H., Ndeezi, G., Grahnquist, L., Olafsdottir, E., et al. 2010. Helicobacter pylori in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based cross sectional survey. *BMC Gastroenterology*, 10, 62-9.
- Htun, N. S. N., Odermatt, P., Müller, I., Yap, P., Steinmann, P., Schindler, C., et al. 2018. Association between gastrointestinal tract infections and glycated hemoglobin in school children of poor neighborhoods in Port Elizabeth, South Africa. *PLOS Neglected Tropical Diseases*, 12, 630-8.
- Hussain, Z., El-Omar, E. & Lee, Y. Y. 2020. Dual infective burden of Helicobacter pylori and intestinal parasites: Good or bad news for the host? *Indian Journal of Gastroenterology*, 39, 111-116.
- Ibrahim, A., Ali, Y. B. M., Abdel-Aziz, A. & El-Badry, A. A. 2019. Helicobacter pylori and enteric parasites co-infection among diarrheic and non-diarrheic Egyptian children: seasonality, estimated risks, and predictive factors. *Journal of Parasitic Diseases*, 43, 198-208.
- Kadi, R. H., Halawani, E. M. & Abdelkader, H. S. 2014. Prevalence of H. pylori strains harbouring cagA and iceA virulence genes in Saudi patients with gastritis and peptic ulcer disease. *Microbiology Discovery*, 2, 2-9.
- Kakiuchi, T., Nakayama, A., Shimoda, R. & Matsuo, M. 2019. Atrophic gastritis and chronic diarrhea due to Helicobacter pylori infection in early infancy: A case report. *Medicine (Baltimore)*, 98, 179-86.
- Krogsgaard, L. R., Engsbro, A. L., Stensvold, C. R., Nielsen, H. V. & Bytzer, P. 2015. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study. *Clinical Gastroenterology and Hepatology*, 13, 507-513.
- Kusters, J. G., van Vliet, A. H. & Kuipers, E. J. 2006. Pathogenesis of helicobacter pylori infection. *Clinical Microbiology Reviews*, 19, 449-90.
- Majid, M. F., Kang, S. J. & Hotez, P. J. 2019. Resolving "worm wars": An extended comparison review of findings from key economics and epidemiological studies. *PLOS Neglected Tropical Diseases*, 13, 69-73.
- Malfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J. M., Peek, R., Schulz, C., et al. 2023. Helicobacter pylori infection. *Nature Reviews Disease Primers*, 9, 19-25.
- Marie, M. A. 2012. Relationship between Helicobacter pylori virulence genes and clinical outcomes in Saudi patients. *Journal of Korean Medical Science*, 27, 190-3.
- Momenah, A. M. & Tayeb, M. T. 2007. Helicobacter pylori cagA and iceA

- genotypes status and risk of peptic ulcer in Saudi patients. *Saudi Medical Journal*, 28, 382-5.
- Moreira, E. D., Jr., Nassri, V. B., Santos, R. S., Matos, J. F., de Carvalho, W. A., Silvani, C. S., et al. 2005. Association of *Helicobacter pylori* infection and giardiasis: results from a study of surrogate markers for fecal exposure among children. *World journal of gastroenterology: WJG*, 11, 2759-63.
- Ng, Q. X., Foo, N. X., Loke, W., Koh, Y. Q., Seah, V. J. M., Soh, A. Y. S., et al. 2019. Is there an association between *Helicobacter pylori* infection and irritable bowel syndrome? A meta-analysis. *World journal of gastroenterology: WJG*, 25, 5702-5710.
- Obaid, J., Ayoon, A. N. N., Almurisy, O. N. M., Alshuaibi, S. M. S. & Alkhwilani, N. N. 2021. Evaluation of antibody immunochromatography testing for diagnosis of current *Helicobacter pylori* infection. *Practical Laboratory Medicine*, 26, 245-52s.
- Okyay, P., Ertug, S., Gultekin, B., Onen, O. & Beser, E. 2004. Intestinal parasites prevalence and related factors in school children, a western city sample--Turkey. *BMC Public Health*, 4, 64-73.
- Passaro, D. J., Taylor, D. N., Meza, R., Cabrera, L., Gilman, R. H. & Parsonnet, J. 2001. Acute *Helicobacter pylori* infection is followed by an increase in diarrheal disease among Peruvian children. *Pediatrics*, 108, 87-91.
- Perandin, F., Pomari, E., Bonizzi, C., Mistretta, M., Formenti, F. & Bisoffi, Z. 2018. Assessment of Real-Time Polymerase Chain Reaction for the Detection of *Trichostrongylus* spp. DNA from Human Fecal Samples. *American Journal of Tropical Medicine and Hygiene*, 98, 768-771.
- Piubelli, C., Soleymanpoor, H., Giorli, G., Formenti, F., Buonfrate, D., Bisoffi, Z., et al. 2019. Blastocystis prevalence and subtypes in autochthonous and immigrant patients in a referral centre for parasitic infections in Italy. *PLOS One*, 14, 210-8.
- Pomari, E., Ursini, T., Silva, R., Leonardi, M., Ligozzi, M. & Angheben, A. 2020. Concomitant Infection of *Helicobacter pylori* and Intestinal Parasites in Adults Attending a Referral Centre for Parasitic Infections in North Eastern Italy. *Journal of Clinical Medicine*, 9, 70-3.
- Ruenchit, P. 2021. State-of-the-Art Techniques for Diagnosis of Medical Parasites and Arthropods. *Diagnostics (Basel)*, 11, 25-8.
- Sabah, A. A., Gneidy, M. R. & Saleh, N. M. 2015. Prevalence of *Helicobacter pylori* infection among adult patients with different gastrointestinal parasites in Tanta City district. *Journal of the Egyptian Society of Parasitology*, 45, 101-6.
- Salama, R. I., Emara, M. H., Mostafa, H. M., Abd-Elsalam, S., Alnabawy, S. M., Elshweikh, S. A., et al. 2019. *Helicobacter pylori* infection and risk of salmonella infection. *Medicine (Baltimore)*, 98, 1430-9.
- Savoldi, A., Carrara, E., Graham, D. Y., Conti, M. & Tacconelli, E. 2018. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology*, 155, 1372-1382.
- Seid, A., Tamir, Z., Kasanew, B. & Senbetay, M. 2018. Co-infection of intestinal parasites and *Helicobacter pylori* among upper gastrointestinal symptomatic adult patients attending Mekanusalem Hospital, northeast Ethiopia. *BMC Research Notes*, 11, 144-7.

- Selbuz, S. & Buluş, A. D. 2020. Gastrointestinal symptoms in pediatric patients with type 1 diabetes mellitus. *Journal of Pediatric Endocrinology and Metabolism*, 33, 185-190.
- Spotts, H., Walelign, S., Tesfaye, M., Desta, K., Tsegaye, A. & Taye, B. 2020. Concurrent infection of intestinal parasites and *Helicobacter pylori* among school-age children in Central Ethiopia. *Parasite Epidemiology and Control*, 11, 177-83.
- Tilahun, M., Gedefie, A., Belayhun, C., Sahle, Z. & Abera, A. 2022. *Helicobacter pylori* Pathogenicity Islands and *Giardia lamblia* Cysteine Proteases in Role of Coinfection and Pathogenesis. *Infection and Drug Resistance*, 15, 21-34.
- Torres, J., Perez, G. P., Ximenez, C., Muñoz, L., Camorlinga-Ponce, M., Ramos, F., et al. 2003. The association of intestinal parasitosis and *H. pylori* infection in children and adults from a Mexican community with high prevalence of parasitosis. *Helicobacter*, 8, 179-85.
- Verma, S., Venkatesh, V., Kumar, R., Kashyap, S., Kumar, M., Maurya, A. K., et al. 2019. Etiological agents of diarrhea in hospitalized pediatric patients with special emphasis on diarrheagenic *Escherichia coli* in North India. *Journal of Laboratory Physicians*, 11, 68-74.
- Waldum, H. L., Kleveland, P. M. & Sørđal Ø, F. 2016. *Helicobacter pylori* and gastric acid: an intimate and reciprocal relationship. *Therapeutic Advances in Gastroenterology*, 9, 836-844.
- Wroblewski, L. E., Peek, R. M., Jr. & Wilson, K. T. 2010. *Helicobacter pylori* and gastric cancer: factors that modulate disease risk. *Clinical Microbiology Reviews*, 23, 713-39.
- Yakoob, J., Abbas, Z., Khan, R., Tariq, K., Awan, S. & Beg, M. A. 2018. Association of *Helicobacter pylori* and protozoal parasites in patients with chronic diarrhoea. *British Journal of Biomedical Science*, 75, 105-109.
- Yousif Abd Elbagi, Y., Abd Alla, A. B. & Saad, M. B. E. 2019. The relationship between *Helicobacter pylori* infection and intestinal parasites in individuals from Khartoum state, Sudan: a case-control study. *F1000Research*, 8, 209-14.